StockNews.AI
THAR
StockNews.AI
148 days

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

1. Tharimmune's TH023 shows promising preclinical results with higher infliximab delivery. 2. Positive results could boost THAR's market position in immunology.

2m saved
Insight
Article

FAQ

Why Bullish?

Successful preclinical results often lead to increased investor confidence. Similar biotech companies have seen price surges after positive early-stage trial results.

How important is it?

Preclinical success can lead to future funding and partnerships, directly affecting THAR's valuation.

Why Short Term?

Market reactions are typically immediate after positive announcements, influencing THAR's stock within weeks.

Related Companies

IBRXVRTXJAZZ
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations detected being significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection (~3-5µg/ml).

Related News